“Cut-Off Value of Sige To D. Pteronyssinus in Double Negative Patients Der P 1 and Der P2 and Its Clinical Repercussion”.

Antonio Letrán

C. M. ASISA Clinica Dr. Lobatón

Ignacio García

University of Córdoba

Marisa Espinazo-Romeu (✉ marialuisa.espinazo@imibic.org)

Instituto Maimónides de Investigación Biomédica de Córdoba; University of Córdoba; Hospital Universitario Reina Sofía

Carmen Moreno-Aguilar

Instituto Maimónides de Investigación Biomédica de Córdoba; University of Córdoba; Hospital Universitario Reina Sofía

Francisco Moreno

C. M. ASISA Clinica Dr. Lobatón

Research Article

Keywords: Dermatophagoides pteronyssinus, nDer p 1, rDer p 2, biomarker, immunotherapy, molecular diagnosis.

Posted Date: July 16th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-700964/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

“CUT-OFF VALUE OF SIGE TO *D. PTERONYSSINUS* IN DOUBLE NEGATIVE PATIENTS DER P 1 AND DER P2 AND ITS CLINICAL REPERCUSSION”.

Short Title: Allergenic Components in diagnosis decision

Antonio Letrán^{1*}, Ignacio García^{2*}, Marisa Espinazo-Romeu^{3,4^}, Carmen Moreno-Aguilar^{3, 4, 5}, Francisco Moreno¹.

1.- Servicio de Alergología e Inmunología. CM ASISA Lobatón. Cádiz.

2.- Servicio de Alergología y Neumología. Hospital Quirón Salud Campo de Gibraltar. Cádiz.

3.- Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Cordoba, Spain

4.- National Network ARADyAL. Health Institute Carlos III, Madrid, Spain.

5.- Department of Immunology and Allergy, Reina Sofia University Hospital, Cordoba, Spain

* Both authors contributed equally

^Corresponding author:

Marisa Espinazo Romeu. GC01 Laboratorio de Inmunología y alergia. IMIBIC. Avenida Menéndez Pidal, S/N, 14004, Córdoba. Spain

e-mail: marialuisa.espinazo@imibic.org

Word Count: 3359

Table: 1 Figures: 5

Funding source: None

Conflict of Interest

The authors declare that they have no conflicts of interest.

“CUT-OFF VALUE OF SIGE TO *D. PTERONYSSINUS* IN DOUBLE NEGATIVE PATIENTS DER P 1 AND DER P2 AND ITS CLINICAL REPERCUSSION”.

Background: Accessibility to more precise diagnostic techniques such as component resolved diagnostics (CRD), provides us with an important advance in diagnostic aspects as well as treatment.

Objective: The subject of this study aims to better understand the profiles of sensitization to Der p 1, Der p 2 and Der p 23 and to know to what extent their use could help us in optimizing the decision-making for their treatment with Specific Immunotherapy.

Method: Cross-sectional study of subjects older than 5 years, diagnosed with allergy to HDM using skin prick test and sIgE, with symptoms of rhinitis and/or asthma. Total and specific IgE was determined to *D. pteronyssinus*, nDer p 1, rDer p 2 and rDer p 23 using ImmunoCAP.

Results: 240 patients were recruited (97.1% rhinitis and 46.25% rhinitis and asthma). Four different phenotypes were observed: positive or negative for sIgE nDer p 1 and/or IgE rDer p 2. 17% of these patients sIgE were double negative for Der p 1 and Der p 2 (increasing with age and with significantly lower sIgE levels than the rest of the groups). Using ROC curves, value less than 2.18 KU_A/L for *D. pteronyssinus* sIgE gave us a sensitivity and specificity of 0.882 and 0.985, respectively, to double negative IgE nDer p 1 and IgE rDer p 2 group.

Conclusions: Despite positive SPT and sIgE to *D. pteronyssinus*, 17% of the studied population is IgE nDer p 1 and IgE rDer p 2 double negative, with a cut-off value of 2.18 KU/ L, which is very relevant for taking of decisions in prescription of AIT. The double positive population sIgE nDer p 1 and IgE rDer p 2 is

associated with asthma compared to the other groups and this does not seem to be influenced by IgE rDer p 23.

Key words; *Dermatophagoides pteronyssinus*, nDer p 1, rDer p 2, biomarker, immunotherapy, molecular diagnosis.

Introduction

House dust mite (HDM) represents a major source of allergens affecting a high number of people worldwide¹. In moderate climate countries, mite allergic patients, are co-exposed and co-sensitized to allergens from both *D. pteronyssinus* (*Dptr*) and *D. farinae* species². Batard et al. (2016) suggested that to design allergen products suitable to treat HDM – allergic patients in various parts of the world, it is very important to understand the IgE sensitization profile to allergens from *Dermatophagoides* species. Among mite group 1 and 2 allergens are clearly the most important ones, both in terms of prevalence and relative contribution to total specific IgE (sIgE) reactivity against HDM allergens, being the most relevant to European patients³. Molecular allergy diagnostics has become an important tool in daily routine in allergy centers. The knowledge about major and minor allergen components and their prevalence opened new possibilities in allergy diagnostics and therapy^{4, 5}. As a consequence of these findings, molecular diagnostics for major allergen components should be mandatory before immunotherapy (ITA) in HDM allergic patients. For diagnostic purposes, measurement of specific antibodies to HDM extracts could be a safe and routine procedure with high value estimates of sensitivity and specificity in both nDer p 1 (Derp1) and rDer p 2 (Derp2) supported the use in the diagnosis of *Dptr* and optimizing immunotherapy outcome⁵. Previous studies have shown

in populations with either low exposure to HDM or a small number of patients, the proportion of patients that show to be sIgE nDer p 1 (IgEDerp1), sIgE rDer p 2 (IgEDerp2) double positive or positive to only one of them or double negative to both^{4, 6, 7}. But the current diagnosis of *Dptr* allergy is based on a clinical history of allergic symptoms and a skin-prick test (SPT) by using crude extracts from mites, without sufficient knowledge of Der p 1 and Der p 2 profile in a population exposed to a high allergenic load for HDM⁸ or how to use it in daily clinical practice. The aim of the present study was to investigate the profile of Derp1, Derp2 and Der p 23 (Derp23) allergens in mite-sensitized patients and draw practical conclusions for daily practice or involvement in making decisions for immunotherapy.

Materials and Methods.

Study population

We conducted a cross-sectional study covering 240 consecutive HDM allergic patients attended in Southern Spain (Clínica Lobatón and QuirónSalud Gibraltar area, both in the coastal area). The local weather is warm and humid, and mites are the most relevant inhalant allergens⁸. Routine diagnosis was established through the association between a typical history of allergic symptoms for either rhinitis, according to ARIA criteria¹ or asthma according to GEMA criteria⁹ and the presence of sensitization (positive Skin Prick Test (SPT), all of them with the intention of being treated with AIT.

Main determinations

Skin prick testing

SPT was performed with a solution for HDM from LETI lab. S.L.U. The procedure was in agreement with published guidelines¹⁰.

Serological analysis

Total IgE levels, sIgE to *Dptr*, Derp1, Derp2, Derp23, were measured by ImmunoCAP (ThermoFisher Scientific, Uppsala, Sweden) according to the manufacturer's instructions. Total IgE levels were expressed in international units per unit volume (kU/L), sIgE levels were expressed in kU_A/L. Values $\geq 0,35$ kUA/L were considered positive.

Statistical analysis

Demographic characteristics of patients were expressed as mean $\pm$ standard deviation (SD) for continuous variables and as frequency distribution for categorical variables. All the cellular variables were expressed as median (minimum, maximum).

Wilcoxon rank sum, Kruskal-Wallis chi-squared and Fisher test with alternative hypothesis of two-sided tests were used to determine the overall differences between the four groups and clinical symptoms: sIgE nDer p1 (IgEDerp1) and IgE rDer p2 (IgEDerp2) positive patients (DP), IgEDerp1 positive and IgEDerp2 negative patients (DP1), IgEDerp1 negative and IgEDerp2 positive patients (DP2) and IgEDerp1 and IgEDerp2 negative patients (Double Negative) (DN). Furthermore, post-hoc tests were performed for multiple comparisons using None, Holm and Bonferroni correction of p-values. Samples were significantly different when $p\text{-value} < 0.05$ in the three methods. ROC curves were performed under parametric conditions. R statistical software (versión 3.5.0) was used to perform all the analyses.

Ethics

The study was approved by the local Ethical Committee of our Institution with the recommendations of the Declaration of Helsinki. Informed consent was signed by all subjects or parents/guardians for participants <18 years old.

Results

Two hundred and forty subjects were recruited for this study. All of them was sensitized to *Dptr* by SPT and IgE to *Dptr* by Immucap System. Characteristics of the study population are summarized in Table 1.

Prevalence of sensitization and levels of sIgE to *Dptr* and their components nDer p 1, rDer p 2 and rDer p 23.

67% of the patients were found sensitized Double Positive (DP), 17% were not sensitized to nDerp1 and rDerp2 (DN) and IgEDerp1 positive and IgEDerp2 negative patients (DP1) and IgEDerp1 negative and IgEDerp2 positive patients (DP2) were found sensitized in a 7% and 9% respectively, being DN significantly higher than the proportion of DP1 or DP2 patients (Figure 1a). However, the production of sIgE against *Dptr* varies significantly between DP1 and the rest of the groups, being significantly lower in DN group, being the range of median valor of 26,5 KU_A/L and 0,90 KU_A/L, respectively (Figure 1b). ROC curve analysis show that a cut-off point to complete extract-specific IgE where values lower than 2.18 KU_A/L implies that sIgE nDerp 1 and sIgE rDerp 2 was negative (Figure 1c).

Adjusted the sIgE production to *Dptr* by each group (DP, DP1, DP2 and DN) according to age quartiles, there is an increasing trend of the DN group according to age, as well as a slight decrease in group DP2. (Figure 2).

The production of IgEDerp1 versus IgEDerp2 does not maintain a linear correlation, with statistically significant curve slopes. (Figure 3).

Relationship between sIgE nDer p 1, sIgE rDer p 2 and sIgE rDer p 23 in each group.

In the total sample, in comparison DP, DP1 and DP2 groups was observed as DP had higher levels for IgEDer p1 and IgEDerp2 between these groups without reaching statistical significance between them (Fig 4). sIgE rDer p 23 (IgEDerp23) is present in 69.2% of the total sample, with a clear difference in each group, both in frequency and in levels of sIgE. IgEDerp23 positive in DP group positive was present in 90% of the sample. In DP1 and DP2 was present in 50% of the sample and in the DN group was present in 75% of the sample IgEDerp23 showed significant values in DP and DP2 groups (median 2.99 and 5.43 KU/L sIgE respectively), with respect to DP1 or DN. In DN group IgEDerp23 showed a high frequency of low values of IgEDerp23 that constitute 75% (mean sIgE 0.84 ± 1.9).

Prevalence of sensitization and levels of sIgE to nDer p 1, rDer p 2 and rDer p 23, according to clinical diagnosis, in each group.

Rhinitis

There were significant differences between the studied groups in relationship with presence of rhinitis, being predominant in the whole sample. The percentage of patients where rhinitis predominated versus asthma was significantly higher in

the DN and DP2 group (Figure 5). In the DN group, persistent mild rhinitis (grade 2) predominated. The rest of the groups severity grades 2 and 3 predominated over grade 1 (Fig. 1 suppl.). We did not find statistically significant differences in the production of IgEDerp1, IgEDerp2 or IgEDerp23 in the different degrees of severity.

Asthma.

There was a different distribution of asthma severity depending on the groups. In the DP group, the three degrees of severity of asthma coexisted, with no predominance of one over the other. Grade 1 and 3 predominated in the DP2 group. Grade 1 clearly predominated in the DP1 group with grade 3 absent. Grade 1 and 2 predominated in the DN group. There were no differences in the IgEDerp23 values in the absence of asthma or its presence in any of the degrees of severity (Fig. 2 suppl.).

As the same as rhinitis, comparing the different groups with each other, DP, followed by DP2 and DP1 group, showed highest to lowest value of sIgE, without significant differences. There were statistically significant differences between the DP group with respect to DN (Figure 5).

Discussion

In the studied population, patients with ≥ 5 years old have been selected. Inclusion criteria were sensitization profile defined at least for IgEDerp1, IgEDerp2 or IgEDerp23, as well as their sIgE to *Dptr* must be positive $\geq 0,35$ kUA/L measured by Immunocap System¹¹. The allergenic burden for house mites is significantly

higher in southern European countries¹². However, as a whole, for the diagnosis of sensitization to HDM, IgEDerp1 and IgEDerp2 are sufficient as the most relevant allergens and capable of diagnosing >95% of patients^{3, 13}. Our series shows the presence of the 4 phenotypes in production for IgEDerp1 and IgEDerp2^{3, 6, 7, 14, 16}. The majority group DP (IgEDerp1 and IgEDerp2 double positives), significantly higher, followed by DN (double negative to IgEDerp1 and IgEDerp2) being the second most relevant group. Groups DP1 and DP2 formed a minority group. DN group constitutes 17% in the total sample. However, we can see that the percentage of DN patients varies according to age, with an increasing trend towards older age. This indicates more years of exposure increases the possibility of developing sensitization to minor allergens present in mites. Although the pattern of sensitization is defined at relatively early ages¹¹, everything seems to indicate that there is an important group that will progressively increase from 12% (in those under 18 years of age) to 26% (in those over 45 years of age). DN group is a very significant value to take into account in two fundamental aspects: initiation of AIT or inclusion in clinical trials for this treatment. This double negative group to IgEDerp1 and IgEDerp2 is sensitized to minority allergens¹⁷. DN group patient's shows a low response in the production of sIgE for the complete extract of *Dptr*, therefore it may influence its use as an AIT response biomarker¹⁸. Although the use of AIT in those that are only IgEDerp1 or IgEDerp2 positive is justified, since the recommendation is that the extracts contain known amounts of these allergens, the use of AIT in the double negatives for IgEDerp1 and IgEDerp2 is empiricism, we don't know the answer. In daily clinical practice, we cannot know which minority allergen the patient is allergic to and whether the extract administered contains it, or whether

it is equally present in all its batches, or its concentration. Unless for immunotherapy clinical trials, this double negative group Derp1 and Derp2, should be excluded.

In daily clinical practice, a clinical history of allergy to HDM, with concordant positive skin tests, let us diagnosis to the patients. Despite the progress and development evolution makes by the components resolving diagnostic (CRD), these are not routinely performed for diagnosis, either because of the cost or because they are not considered useful enough. With the results obtained, values of sIgE to complete extract of *Dptr* in population older than 5 years old, lower than 2.18 KU_A / L; we would be possibly in the double negative group for IgEDerp1 and IgEDerp2. The cost for testing IgEDerp1 and IgEDerp2 prior to AIT could be reduced by selecting only patients with lower values at 2.18 KU_A/L. Logically, this is valid only in the geographical area with a similar allergenic load and more studies are needed to establish an overall value that discriminates the DN group.

Our results show that the levels of IgEDerp2 is higher than IgEDerp1^{13, 6, 7, 14, 16} without reaching statistical significance. However, since the sIgE production describes a non-linear curve and the commonly used method is an ELISA whose curve is not linear either, we can only say that there is a higher sIgE production for HDM group 2. This cannot be used to measure the quantity of allergens present in the immunotherapy extracts. But both Derp1 and Derp2 allergens must be present, at least in the same proportion.

IgEDerp23 is present in a very different grade in each of the groups studied, which for the total sample is 63%. IgEDerp23 seems to be a relevant allergen both in frequency and in sIgE production in the USA, but it does not seem to be as relevant in Europe³. In our sample, IgEDerp23 is mainly present in the double positive group IgEDerp1 and IgEDerp2 along. It is very striking, in the group positive for IgEDerp1 it does not have levels of IgEDerp23. Both are allergens present in the faeces. However, if it is present in the positives only to IgEDerp2 group, an allergen present in the body of the mite. It appears that in the absence of Derp1 sensitization, the immune system responds to Derp23 as an allergen present in faeces. Patients sensitized only to Derp1 or only Derp2, both constitute a small number of the sample (16%) [17, 19]. In our results, in the group double negative to IgEDerp1 and IgEDerp2 (DN), the 75% of them are IgEDerp23 positive, with low values of sIgE with mean 0.89 ± 2.01 KU_A/L and median 0.08 (7.60-0.0) KU_A/L. Everything seems to indicate that IgEDerp23 has a high prevalence but little relevance, since in the DP the most frequent is sensitized to Derp1, Derp2 and other allergens including Derp23, while in the DN group, the production of sIgE produced is very low and contributes little to the total sIgE compared to IgEDerp23 produced. In a recent study in children, where the pattern of sensitization Derp1, Derp2 and Derp23 was studied¹⁹, the DN percentage was 9.4%, associating the presence of moderate – severe asthma when the three allergens coexisted. However, in the DN rhinitis prevailed over asthma. In a recent study, no association was found between the presence of IgEDerp23 and response to AIT, although it was present in 88% of the sample studied²⁰.

There is great controversy whether the frequency or levels of IgEDerp1 or IgEDerp2 or other CRDs, is associated with the respiratory symptoms of patients,

be it rhinitis or asthma. As Posa describes in his work¹¹, summarized with very interesting conclusions in a review²¹, higher exposure to mites were associated with a broader polymolecular IgE sensitization pattern. Participants achieve the broadest IgE sensitization stage, depending on the sensitization pattern A, B or C. The ABC pattern had significantly higher risk of mite-related AR and asthma than unsensitized participants. IgEDerp1 or IgEDerp23 at age 5 years or less predicted asthma at school age. Five hundred and one adolescent were recruited in Salzburg, showing that in alpine areas, less exposure to allergens, less sIgE response and less clinical severity were found, but not less house dust mite allergic people. Group 2 allergens predominated in the houses and the response of sIgE production (measured by ISAC micro-array platform) was greater for IgEDerp2 [15]. With our results we have not found differences between rhinitis and asthma in the total sIgE versus complete extract, no differences for the group IgEDerp1 and/or IgEDerp2, but if it appears in the double negative group IgEDerp1 and IgEDerp2 where rhinitis predominates. This is very curious, because in the group IgEDerp1 negative but IgEDerp2 positive that also has IgEDerp23, there is no higher frequency of asthma, this makes us think that by itself both IgEDerp2 and IgEDerp23, are not relevant to the presence of asthma. Fifty-seven of the studied patients were younger than 18 years old, corresponding to 23,6% of our studied population. 64,9% of them belong to DP group, 15,8% to DP1, 12,28% to DN and 7,01% of DP2 group. Of this patients group, a 57% suffered asthma, with this distribution: In the DP group the 67% of them suffered asthma, being 48% moderate asthma and 52% intermittent asthma; in the DP1 group, the 33% of them suffered asthma being 66,7% moderate and 33,3% intermittent asthma; in the DP2 a 50% suffered asthma intermittent and in the

group of DN the 42% of these patients suffered moderate asthma. These data are in agreement with data published by Jiménez-Feijoo¹⁹.

ROC analysis was performed to evaluate the ability of IgE antibodies (IgE Abs) to crude *Dptr* and pure *Dptr* components to predict immediate asthmatic response (IAR) to bronchoprovocation [22]. The AUCs (Area under curve) for the levels of IgE Abs to IgEDerp1 and IgEDerp2 were 0.913 (95% confidence interval (CI), 0.817e1.000) and 0.906 (95% CI, 0.801e1.000), respectively, comparable for *Dptr* (0.920; 95% CI, 0.828e1.000). It shown the relationship between the levels of IgE Abs and IAR positivity predicted using a logistic regression model. The curves show ascending slopes in which an increasing IgE concentration value corresponds to a higher probability of IAR positivity. It shown diagnostic values of IgE Abs to crude *Dptr*, IgEDerp1, and IgEDerp2 at different cut-off points. IgE Abs to crude *Dptr* showed good diagnostic values at the cut-off point of 3.5 kUA/L. Taking these data together with our results, the patients included in the DN group (IgEDerp1 and IgEDerp2 double negative) with asthma and lower values of 3.5 KU_A/L to HDM, we must think of another allergen or cause as responsible for your asthma.

The differences in the response or pattern of sensitization to the different allergens and the presence or absence of asthma are documented, as well as their possible relationship with age^{23, 24, 25}. Symptomatic patients recognize more HDM allergens than asymptomatic subjects. The frequency of sensitization to Derp1 and Derp2 was the same, although not all positive patients were sensitized to both allergens. Sensitization to Derp5 was also highly prevalent in both groups.

Differences were observed in the frequency of sensitization to Der p 7 and Derp23. The sIgE to Der p 4, Der p 10, Der p 11, Der p 14, Der p 15, Der p 18 and Der p 21 were no significant difference between the symptomatic patients and asymptomatic subjects²⁴, low sample size (n = 17 and 19 symptomatic and asymptomatic, respectively). Significantly higher concentrations of IgEDerp1 and IgEDerp2 were observed in patients with asthma than in those without asthma²⁶,²⁷. As same as our results, 11% of the patients were DN and sIgE levels to certain HDM allergens Derp1, Derp2, Der p 5 and Derp23 were significantly higher in asthmatic children than children without asthma. There was also no correlation between age and the number of recognized allergens. Patients with IgE reactivity to Der p 5 and a probability of 85% of having asthma²⁵.

As Vidal C.²⁸ in the DP group there is a greater presence of asthma than in the DN in a significant way, but we also found it in the DP2 group (IgEDerp2 without IgEDerp1). However, we find differences regarding the severity of asthma, being predominantly milder (grade 1) for the DP1 and DN group with respect to DP or DP2. The frequency of asthma does not vary by groups or the presence or absence of Derp23.

Anyway, we have to understand that, the differences in the production of sIgE for rhinitis and asthma in allergic patients allergic to HDM, is artificial.

Conclusion.

The availability of CRD allows us to visualize the sensitization profile of patients allergic to complete allergens. Possibly the same phenomenon is being viewed from different perspectives. In this sense, the debate between prevalence and relevance arises. Even considering only the most prevalent for HDM, available in

daily practice, such as Derp1, Derp2 and Derp23, we found serious differences in various studies. In our study we found a clinical relationship, in rhinitis with or without asthma, regarding the groups double positive to IgEDerp1 and IgEDerp2, positive only to one of them or double negative to both. In addition to being able to establish a point of cut-off from which follows the complete extract, allows us to predict the double negative group IgEDerp1 and IgEDerp2 and its clinical repercussion. Derp23 is a prevalent allergen but we found no clinical relevance. More robust studies are needed in the number of patients and in representative areas of high HDM allergenic load, so that the CRD tools can be used as a diagnosis, or prognosis or marker of some clinical characteristic useful in daily practice, for example indication of AIT.

References

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy* 2008;63(suppl 86):8–100.
2. Wayne R. Thomas. Hierarchy and molecular properties of house dust mite allergens. *Allergology International* 2015;64:304-11.
3. Bartard T, Baron – Bodo V, Martelet A, Le Mignon M, Lemoine P, Jain K, et al. Patterns of IgE sensitization in house dust mite – allergic patients: implications for allergen immunotherapy. *Allergy* 2016;71:220-9.
4. Becker S, Schleder T, Kramer MF, Haack M, Vrtala S, Resch Y et al. Real – life study for the diagnostic of house dust mite allergy – The value

of recombinant allergen based IgE serology. Int Arch Allergy Immunol
2016;170:132–7.

5. Tian M, Zhou Y, Zhang W and Cui Y. Der p 1 and Der p 2 specific
immunoglobulin E measurement for diagnosis of *Dermatophagoides*
pteronyssinus allergy: A systematic review and meta-analysis. Allergy
Asthma Proc 2017;38:333-42.

6. Gellrich D, Högerle C, Becker S and Gröger M. Is quantitative sIgE
serology suitable for distinguishing between silent sensitization and
allergic rhinitis to *Dermatophagoides pteronyssinus*? J. Investig Allergol
Clin Immunol 2019;29(2):124-31.

7. Taketomi EA, Solva DAO, Sopelete MC, Gervasio AM, Alves R and Sung
SJ. Differential IgE reactivity to Der p 1 and Der p 2 allergens of
Dermatophagoides pteronyssinus in mite – sensitized patients. J Investing
Allergol Clin Immunol 2006;16(2):104-9.

8. MAPA ACAROLÓGICO DE ESPAÑA. 2009. Laboratorios LETI. Ed.
Elsevier España, S.L.,

9. Plaza, V. GEMA 2009 Spanish asthma management guide. J Investing
Allergol Clin Immunol 2010;20 suppl 1;9-18.

10. Heinzerling L, Mari A, Bergmann K-C, Bresciani M, Burbach G, Darsow U,
et al. The skin prick test – European standards. Clinical and Translational
Allergy 2013;3:3.

11. Posa D, Perna S, Resch Y, Lupinek C, Panetta V, Hofmaier S, et al.
Evolution and predictive value of IgE responses toward a comprehensive
panel of house dust mite allergens during the first 2 decades of life. J
Allergy Clin Immunol 2017;139:541-9.

12. Zock JP, Heinrich J, Jarvis D, Verlato G, Norbäck D, Plana E, et al. Distribution and determinants of house mite dust allergen in Europe: The European Community Respiratory Health Survey II. *J Allergy Clin Immunol* 2006;118:682-90.
13. Weghofer M, Thomas WR, Kronqvist M, Mari A, Purohit A, Pauli G, et al. Variability of IgE reactivity profiles among European mite allergic patients. *Eur J Clin Invest* 2008;38 (12):959–65.
14. Barber D, Arias J, Boquete M, Cardona V, Carrillos T, Gala G, et al. Analysis of mite allergic patients in a diverse territory by improved diagnostic tools. *Clinical and Experimental Allergy*. 2012;42:1129–38.
15. Stemeseder T, Schweidler B, Doppler P, Klinglmayr E, Moser S, Lueftenegger L, et al. Exposure to Indoor Allergens in Different Residential Settings and Its Influence on IgE Sensitization in a Geographically Confined Austrian Cohort. *PLOS ONE* 2017; January 3:1-17.
16. Peixoto S, Soares J, Monteiro T, Carvalho M, Santos M, Simoes C, et al. Evaluación de la sensibilización a Der p 1 y Der p 2 en una población pediátrica del Norte de Portugal. *An Pediatr (Barc)*. 2018;89(3):162-9.
17. Mateos Senedo F, Dorofeeva Y, Pires AP, Tomaz E, Taborda Barata L, Inácio F, et al. Der p 23: Clinical Relevance of Molecular Monosensitization in House Dust Mite Allergy. *J Investig Allergol Clin Immunol* 2019;29(4):294-332.
18. Shamji MH, J. H. Kappen JH, Makdis M, E. Jensen-Jarolim E, Knol EF, Klein-Tebbe J, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. *Allergy* 2017; 72(8):1156-73

19. Jimenez – Feijoo R, Pascal M, Moya R, Riggioni C, Dominguez O, Lózano J, et al. Molecular diagnosis in house dust mite-allergic patients suggests that Der p 23 is clinically relevant in asthmatic children. *J. Investing Allergol Clin Immunol* 2020;30(2):127-32
20. Arroabarren E, Echechipía S, Galbete A, Lizaso MT, Olaguibel JM, Tabar AI. Association Between Component-Resolved Diagnosis of House Dust Mite Allergy and Efficacy and Safety of Specific Immunotherapy. *J Investig Allergol Clin Immunol* 2019;29(2): 164-7.
21. Posa D, Hofmaier S, Arasi S and Matricardi PM. Natural Evolution of IgE Responses to Mite Allergens and Relationship to Progression of Allergic Disease: a Review. *Curr Allergy Asthma Rep* 2017;17:28.
22. Minami T, Fukutomi Y, Lidholm J, Yasueda H, Saito A, Kiyoshi S, et al. IgE Abs to Der p 1 and Der p 2 as diagnostic markers of house dust mite allergy as defined by a bronchoprovocation test. *Allergology International* 64 2015;1:90-5
23. Yang X, Fan G and Li J. Diagnostic value of Der p 1 and Der p 2 specific IgE in *Dermatophagoides pteronyssinus* IgE sensitization. *Ann Allergy Asthma Immunol.* 2016;116:295-301.
24. Zidarn M, Robic M, Krivec A, Solar M, Resch-Marat Y, Vrtala S, et al. Clinical and immunological differences between asymptomatic HDM-sensitized and DM-allergic rhinitis patients. *Clin Exp Allergy.* 2019;49(6):808-18.
25. Resch Y, Michel S, Kabesch M, Lupinek C, Valenta R and Vrtala S. Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children. *J Allergy Clin Immunol* 2015;136:1083-91.

- 447 26.Til-Perez G, Carnevale C, Sarria-Echegaray PL, Arancibia-Tagle D,
448 Chugo-Gordillo S and Tomas-Barberan MD. Sensitization profile in
449 patients with respiratory allergic diseases: differences between
450 conventional and molecular diagnosis (a cross-sectional study). Clin Mol
451 Allergy (2019); 17(8):1-9.
- 452 27.Zidarn M, Robic M, Krivec A, Silar M, Resch-Marat Y, Vrtala S, et al.
453 Clinical and immunological differences between asymptomatic HDM-
454 sensitized and DM-allergic rhinitis patients. Clin Exp Allergy
455 2019;49(6):808-18.
- 456 28.Vidal C, Lojo S, Juangorena M and Gonzalez-Quintela A. Association
457 Between Asthma and Sensitization to Allergens of *Dermatophagoides*
458 *pteronyssinus*. J Investig Allergol Clin Immunol 2016;26(5): 304-9.

Table Legends

Table 1. Demographic, clinical and serological characteristics of the studied population

Table 1a) Demographic characteristics of studied population. Data are represented as: Mean±s.d.; Median (Max-min) and variance valor.

Patient's characteristicsc				
Sex (Male/Female)	146/94			
Age (year) Mean ± s.d. Median (Max-min) Variance	33.12 ± 13.33 36 (62-6) 177.67			
	DN	DP1	DP2	DP
	37.78± 15.55 40 (62-6) 241.93	30.71± 13.41 31 (52-7) 179.72	26.24± 14.37 20 (56-7) 206.49	33.08± 12.06 35 (62-12) 145.52

Table 1b) Rhinitis and asthma characteristics depending of the group studied.
Data are represented: n= number of patients; % percentage. GRADE
corresponding to ARIA or GEMA classification

Clinical Characteristic				
Groups	DN	DP1	DP2	DP
RHINITIS (n, %) NO RHINITIS GRADE 1 GRADE 2 GRADE 3	Total patients: 233 (97.1%) 7 (2.9%) 23 (9.6%) 109 (45.4%) 101 (42.1%)			
	2 (4.9%)	0 (0%)	3 (14.3%)	2 (1.2%)
	3 (7.3%)	4 (23.5%)	3 (14.3%)	13 (8.1%)
	26 (63.4%)	5 (29,4%)	8 (38.1%)	70 (43.5%)
	10 (24.4%)	8 (47.1%)	7 (33.3%)	76 (47,2%)
ASTHMA (n, %) NO ASTHMA GRADE 1 GRADE 2 GRADE 3	Total patients: 111 (46,25%) 129 (53.75%) 51 (21.25%) 37 (15.42%) 23 (9,58%)			
	29 (70.73%)	9 (52.94%)	14 (66.67%)	77 (47.83%)
	5 (12.19%)	7 (41.18%)	3 (14.28%)	36 (22.36%)
	6 (14.63%)	1 (5.88%)	1 (4.76%)	29 (18.01%)
	1 (2,44%)	0 (0%)	3 (14.28%)	19 (11.80%)

473 Table 1c) IgE value of studied population. Data are represented as: Mean±s.d.;

474 Median (Max-min) and variance valor. D1: complete extract of D. pteronyssinus

IgE valor (KU/L)				
Groups	DN	DP1	DP2	DP
Total IgE: Mean ± s.d. Median (Max-min) Variance	289.54 ± 377.63 146.75 (2000-2.27) 142604.93			
	274,65± 532,71 86 (1855.0-2.27) 283782.41	241.69± 473.42 65.95 (1779.0-4.1) 224124.58	351.06± 469.01 171.65 (2000-17.5) 219966.50	268.67± 286.93 172 (2000.0-7.80) 82326.41
slgE D1: Mean ± s.d. Median (Max-min) Variance	29.79 ± 34.57 13.90 (181.00-0.07) 1195.36			
	3.00±7,68 0,89 (41.00-0.07) 59.02	13.18± 19.33 6.66 (77.5-0.39) 124.09	21.32± 32.55 11.60 (100-0.68) 1059.26	35.75± 34.72 23.20 (181-1.22) 1205.49
slgE Der p 1: Mean ± s.d. Median (Max-min) Variance	13.96± 21.35 4.33 (100-0.00) 455.66			
	0.09± 0,05 0.1 (0.28-0.0) 2.24*10 ⁻³⁴	9.69± 11.14 4.76 (35.4-0.39) 124.09	0.07± 0.05 0.1 (0.14-0.00) 0.00	17.08± 21.17 8.45 (100.00-0.47) 448.25
slgE Der p 2: Mean ± s.d. Median (Max-min) Variance	16.61± 22.79 6.58 (100-0.00) 519.42			
	0.09± 0.05 0.10 (0.31-0.00) 0.00	0.08± 0.08 0.10 (0.29-0.00) 0.01	17.60± 24.16 9.21 (100.0-0.40) 583.86	20.10± 22.72 11.20 (100.0-0.38) 516.35
slgE Der p 23: Mean ± s.d. Median (Max-min) Variance	4.95 ± 12.79 2.13 (95.90-0.00) 163.47			
	0.89± 2.01 0.08 (7.60-0.0) 4.06	1.33± 2.25 0.17 (5.70-0.04) 5.04	3.74± 3.07 5.43 (5.59-0.19) 9.44	6.30± 15.53 2.80 (95.90-0.00) 241.16

475

476

Figure 1. Prevalence of sensitization and levels of IgE in the different phenotype studied.

Figure 1a) Prevalence of sIgE reactivity to rDer p 1, rDer p 2 in HDM allergic patients in southern o Spain (n = 240).

Figure 1b) Mean value of sIgE D. pteronyssinus to each phenotype. Bar shows statistical difference between phenotype. P-value<0.05

493 Figure 1c) ROC curve about total IgE *D. pteronyssinus*. Cut-off point from which
494 the complete extract-specific IgE valor is positive, but IgE nDer p 1 and IgE rDer
495 p 2 will be negative

496

497

Figure 2. Distribution of the different phenotype in function of the age. Bar means statistical difference $p\text{-value} < 0,05$

Figure 3. Graphic representation of slgE nDer p1 and slgE rDerp2 value for each patient. In the graphic is represented lineal correlation and R² valor. Correlation Pearson= 0.53567; Correlation Spearman= 0.54864.

Figure 4. sIgE median value to different components of *D. pteronyssinus* for each phenotype studied.

Figure 5. Rhinitis/asthma distribution for each phenotype.

Figure 5 a) Percentage of patient in each group suffering rhinitis (No) / rhinitis+asthma (Yes).

Figure 5 b) p-value using different statistical adjust model. When the p-value is lower than 0.05 in the three type of adjust, the sample are considered statistically difference.

RHINITIS/ASTHMA								
P-VALUE ADJUST	DN		DP1		DP2		DP	
	No	Yes	No	Yes	No	Yes	No	Yes
	70.73%	29.26%	52.94%	47.06%	66.67%	33.32%	47.83%	52.17%
NONE	3.4*10⁻⁵		0.55653		0.00085		0.66429	
HOLM	0.00094		1.000		0.02131		1.000	
BONFERRONI	0.00094		1.000		0.02387		1.000	

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementarydata210708derp1223.pdf](#)